a public good project by the
Synthesis
Company
of California

© 2026

C. J. Poole | doi.page

0 works0 citations0 h-index

C. J. Poole

Cambridge University Hospitals NHS Foundation Trust(GB)National Institute for Health Research(GB)Mount Vernon Cancer Centre(GB)University College London(GB)

Publications by Year

Research Areas

Breast Cancer Treatment Studies, HER2/EGFR in Cancer Research, Ovarian cancer diagnosis and treatment, Advanced Breast Cancer Therapies, BRCA gene mutations in cancer

Most-Cited Works

→ Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients(2014)778 cited
→ PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes(2015)301 cited
Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies.(1998)
→ Mortality and stroke after amaurosis fugax.(1985)80 cited
→ aTTom (adjuvant Tamoxifen—To offer more?): Randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor-positive (ER+) or ER untested breast cancer—Preliminary results(2008)69 cited
→ A meta-analysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy.(2009)57 cited

→ Amaurosis fugax under the age of 40 years.(1987)51 cited

→ tAnGo: A randomized phase III trial of gemcitabine (gem) in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy (CT) for women with early-stage breast cancer (EBC)(2008)46 cited

→ A randomised phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab (P) versus carboplatin-based therapy alone in patients with relapsed, platinum sensitive ovarian cancer(2008)26 cited

Overall and subgroup findings of the aTTom trial: A randomised comparison of continuing adjuvant tamoxifen to 10 years compared to stopping after 5 years in 6953 women with ER positive or ER untested early breast cancer(2013)